MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.
Risk Adjusted Net Present Value: What is the current valuation of Roivant Sciences’s Brepocitinib tosylate
The revenue for Brepocitinib tosylate is expected to reach an annual total of $256 mn by 2035 in the US based off GlobalData’s Expiry Model.